UroGen Pharma (URGN) Misses Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
Goldman Sachs Reiterates Neutral Rating on UroGen Pharma (URGN)
August 13, 2024 4:09 PM EDTGoldman Sachs analyst Paul Choi reiterated a Neutral rating and $22.00 price target on UroGen Pharma (NASDAQ: URGN).
The analyst comments "Jelmyto sales flat y/y as focus remains on completing the rolling NDA submission for UGN-102. URGN reported its 2Q24 results... More
